Financial Summary

Equillium, Inc.  (EQ)  $10.37    (%)

  • Symbol
    EQ
    Price
    10.37$
    Beta
    0
    Volume Avrg.
    2457017
    Market Cap
    183383072
    Last Div
    0
    Range
    2.2-27.05
    Changes
    0.27
    Changes Percentage
    Exchange
    NasdaqGS
    Industry
    Biotechnology
    Ceo
    Mr. Bruce D. Steel C.F.A.
    Sector
    Healthcare

About company

Equillium, Inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in La Jolla, California.


Income Statement

Year20192018201720162015201420132012201120102009
Revenue260174.00265595.00229234.00215639.00233715.00182795.0017091.00156508.00108249.0065225.0042905.00
Cost of revenues161782.00163756.00141048.00131376.00140089.00112258.00106606.0087846.0064431.0039541.0025683.00
Gross profit 98392.00 101839.00 88186.00 84263.00 93626.00 70537.00 64304.00 68662.00 43818.00 25684.00 17222.00
Operating expensess34462.0030941.0026842.0024239.0022396.0018034.0015305.0013421.0010028.007299.005482.00
Operating incomes6393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.001174.00
Interest expense3576.00324.002323.001456.00733.00384.00136.000.000.000.000.00
Income tax expenses10481.0013372.0015738.0015685.0019121.0013973.0013118.001403.008283.004527.003831.00
Earnings before taxs65737.0072903.0064089.0061372.0072515.0053483.0050155.0055763.0034205.001854.0012066.00
Net income55256.0059531.0048351.0045687.0053394.003951.0037037.0041733.0025922.0014013.008235.00
Earnings per share basics11.9712.019.278.359.286.4940.0344.6428.0515.411.317
Earnings per share diluteds11.8911.919.218.319.226.4539.7544.1527.6815.151.297
Dividend per shares3.042.742.432.2121.8211.342.63000
Gross margins0.380.380.380.390.40.390.380.440.40.390.4
EBIT margins0.250.270.270.280.30.290.290.350.310.280.28
Profit margins0.210.220.210.210.230.220.220.270.240.210.19
EBITDA76477.0081801.0071501.0070529.0082487.0060449.0055756.0058518.0035604.0019412.00128.00
EBIT6393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.0012066.00
Earnings Before Tax Margins0.250.270.280.280.310.290.290.360.320.280.28
Net Profit Margins0.210.220.210.210.230.220.220.270.240.210.19
0